Schmelter Valerie, Fuerweger Christoph, Muacevic Alexander, Priglinger Siegfried G, Foerster Paul, Liegl Raffael
Department of Ophthalmology, Ludwig-Maximilians University, Munich, Germany.
European CyberKnife Center, Munich, Germany.
Acta Ophthalmol. 2021 Jun;99(4):456-460. doi: 10.1111/aos.14609. Epub 2020 Dec 6.
Vasoproliferative tumours (VPT) are a rare but benign entity that can lead to severe visual acuity deterioration. There is no standard of care, and depending on the degree of clinical features, including tumour size and dissemination, visual acuity and subretinal fluid, treatment options include observation, cryotherapy and brachytherapy. Particularly in larger tumours, brachytherapy has advantages over other options, although higher radiation doses and the need for surgical application are disadvantages of this otherwise effective treatment option. CyberKnife radiosurgery might represent an alternative therapeutic option as no surgical intervention is needed and radiation doses are lower.
All patients diagnosed with vasoproliferative tumors who were treated with CyberKnife radiosurgery with a minimum follow-up time of 12 months were included in this case series. We recorded visual acuity, number of lesions, central retinal thickness with optical coherence tomography (OCT) and reflectivity using A-scan standardizes echography every three months.
A total of four patients with a median age of 34 years (range: 24 - 51) who were observed over an average of 26.5 months (range: 17 - 49 months) matched our inclusion criteria. We appreciated stabilization or increase in visual acuity in all four patients and a regression in tumour thickness with subsequent increase in internal reflectivity as a marker of increasing fibrosis.
We observed good visual and functional outcome following CyberKnife therapy for VPT. We believe that further studies should be pursued to evaluate CyberKnife therapy for the treatment of VPT not treatable with cryo- or lasertherapy.
血管增生性肿瘤(VPT)是一种罕见的良性病变,可导致严重的视力下降。目前尚无标准的治疗方案,根据临床特征的程度,包括肿瘤大小、扩散情况、视力和视网膜下液,治疗选择包括观察、冷冻疗法和近距离放射疗法。特别是对于较大的肿瘤,近距离放射疗法比其他选择具有优势,尽管较高的辐射剂量和手术应用的必要性是这种有效治疗选择的缺点。射波刀放射外科可能是一种替代治疗选择,因为它无需手术干预且辐射剂量较低。
本病例系列纳入了所有经射波刀放射外科治疗的血管增生性肿瘤患者,这些患者的最短随访时间为12个月。我们每三个月记录一次视力、病变数量、使用光学相干断层扫描(OCT)测量的中心视网膜厚度以及使用A扫描标准化超声测量的反射率。
共有4例患者符合纳入标准,中位年龄为34岁(范围:24 - 51岁),平均观察时间为26.5个月(范围:17 - 49个月)。我们观察到所有4例患者的视力稳定或提高,肿瘤厚度消退,随后内部反射率增加,这是纤维化增加的标志。
我们观察到射波刀治疗VPT后视觉和功能预后良好。我们认为应进一步开展研究,以评估射波刀治疗不能用冷冻或激光治疗的VPT的效果。